1 - 25 of 44 results for author:"Marais R." in Literature citations
Results Customize
› Repeat search in UniProtKB (8)
| Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. Smith M.P., Ferguson J., Arozarena I., Hayward R., Marais R., Chapman A., Hurlstone A., Wellbrock C. J. Natl. Cancer Inst. 105:33-46(2013) · Mapped (2) |
| The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Andreadi C., Cheung L.K., Giblett S., Patel B., Jin H., Mercer K., Kamata T., Lee P., Williams A., McMahon M. et al. Genes Dev. 26:1945-1958(2012) · Mapped (13) |
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T. et al. N. Engl. J. Med. 366:207-215(2012) · Mapped (19) |
| Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J. et al. Cancer Cell 20:715-727(2011) · Mapped (10) |
| (V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. Rae J., Viros A., Hayward R., Bennett D.C., Dhomen N., Longley B.J., Reis-Filho J.S., Marais R. J. Invest. Dermatol. 132:488-491(2012) · Mapped (5) |
| ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., Hooper S., Mitter R., Feral C.C., Cook M. et al. Cancer Cell 20:229-245(2011) · Mapped (6) |
| Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Franco A.T., Malaguarnera R., Refetoff S., Liao X.H., Lundsmith E., Kimura S., Pritchard C., Marais R., Davies T.F., Weinstein L.S. et al. Proc. Natl. Acad. Sci. U.S.A. 108:1615-1620(2011) · Mapped (22) |
| Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Arozarena I., Sanchez-Laorden B., Packer L., Hidalgo-Carcedo C., Hayward R., Viros A., Sahai E., Marais R. Cancer Cell 19:45-57(2011) · Mapped (11) |
| BRAF inactivation drives aneuploidy by deregulating CRAF. Kamata T., Hussain J., Giblett S., Hayward R., Marais R., Pritchard C. Cancer Res. 70:8475-8486(2010) · Mapped (10) |
| Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. de Keizer P.L., Packer L.M., Szypowska A.A., Riedl-Polderman P.E., van den Broek N.J., de Bruin A., Dansen T.B., Marais R., Brenkman A.B., Burgering B.M. Cancer Res. 70:8526-8536(2010) · Mapped (5) |
| V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. Carragher L.A., Snell K.R., Giblett S.M., Aldridge V.S., Patel B., Cook S.J., Winton D.J., Marais R., Pritchard C.A. EMBO Mol Med 2:458-471(2010) · Mapped (12) |
| Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation. Ishizaki H., Spitzer M., Wildenhain J., Anastasaki C., Zeng Z., Dolma S., Shaw M., Madsen E., Gitlin J., Marais R. et al. Dis Model Mech 3:639-651(2010) · Mapped (44) |
| A mouse model of melanoma driven by oncogenic KRAS. Milagre C., Dhomen N., Geyer F.C., Hayward R., Lambros M., Reis-Filho J.S., Marais R. Cancer Res. 70:5549-5557(2010) · Mapped (5) |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C. et al. Cell 140:209-221(2010) · Mapped (16) |
| Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. Dhomen N., Da Rocha Dias S., Hayward R., Ogilvie L., Hedley D., Delmas V., McCarthy A., Henderson D., Springer C.J., Pritchard C. et al. Pigment Cell Melanoma Res 23:112-120(2010) · Mapped (5) |
| Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Pinner S., Jordan P., Sharrock K., Bazley L., Collinson L., Marais R., Bonvin E., Goding C., Sahai E. Cancer Res. 69:7969-7977(2009) · Mapped (2) |
| Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Packer L.M., East P., Reis-Filho J.S., Marais R. Pigment Cell Melanoma Res 22:785-798(2009) · Mapped (3) |
| BRAF signaling and targeted therapies in melanoma. Dhomen N., Marais R. Hematol. Oncol. Clin. North Am. 23:529-45, 2009:ix-ix(2009) · Mapped (3) |
| Oncogenic Braf induces melanocyte senescence and melanoma in mice. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Cancer Cell 15:294-303(2009) · Mapped (9) |
| Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Casar B., Arozarena I., Sanz-Moreno V., Pinto A., Agudo-Ibanez L., Marais R., Lewis R.E., Berciano M.T., Crespo P. Mol. Cell. Biol. 29:1338-1353(2009) · Mapped (33) |
| CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Noble C., Mercer K., Hussain J., Carragher L., Giblett S., Hayward R., Patterson C., Marais R., Pritchard C.A. Mol. Cell 31:862-872(2008) · Mapped (5) |
| Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. Wellbrock C., Rana S., Paterson H., Pickersgill H., Brummelkamp T., Marais R. PLoS ONE 3:e2734-e2734(2008) · Mapped (8) |
| BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Banerji U., Affolter A., Judson I., Marais R., Workman P. Mol. Cancer Ther. 7:737-739(2008) · Mapped (8) |
| In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., Marais R. Cancer Res. 66:9483-9491(2006) · Mapped (12) |
| FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Pardo O.E., Wellbrock C., Khanzada U.K., Aubert M., Arozarena I., Davidson S., Bowen F., Parker P.J., Filonenko V.V., Gout I.T. et al. EMBO J. 25:3078-3088(2006) · Mapped (7) |